Literature DB >> 11606079

Expression of cell cycle proteins in ovarian carcinoma cells in serous effusions-biological and prognostic implications.

B Davidson1, B Risberg, A Berner, J M Nesland, C G Tropé, G B Kristensen, M Bryne, M Goscinski, G van de Putte, V A Flørenes.   

Abstract

OBJECTIVE: The aim of this study was to investigate the expression of cell cycle proteins in ovarian carcinoma cells in serous effusions and respective solid tumors.
METHODS: Fifty-five malignant effusions and 38 tumors (20 primary, 18 metastatic) were immunohistochemically stained for cyclin A, p27(kip1), and Ki-67. Staining extent (0-100% cells) and intensity (0-3 scale) were scored. Cyclin A and p27(kip1) expression was additionally studied in 29 malignant effusions using immunoblotting. Immunohistochemistry results in effusions were evaluated for possible association with clinicopathologic parameters.
RESULTS: Nuclear immunoreactivity for all markers was detected on carcinoma cells in the majority of effusions using immunohistochemistry. Similarly, immunoblotting showed the presence of cyclin A and p27(kip1) in 29/29 and 25/29 specimens, respectively. Intense (3) immunoreactivity for Ki-67 was detected more often in peritoneal effusions, compared with those of pleural location (P = 0.036). Staining in primary and metastatic lesions was generally comparable to that of tumor cells in effusions. Staining for p27(kip1) was more diffuse in effusion specimens obtained prior to the institution of chemotherapy (P = 0.042). In an analysis of all effusions, an association was observed between the number of cells that were immunoreactive for Ki-67, cyclin A, and p27(kip1) (cyclin A-Ki-67: P = 0.008; p27(kip1)-Ki-67: P = 0.019; cyclin A-p27(kip1): P = 0.032). In survival analysis, the presence of more diffuse (P = 0.042) and intense (P = 0.019) staining for cyclin A correlated with prolonged overall survival.
CONCLUSIONS: The expression of the studied cell cycle markers does not differ markedly between ovarian carcinoma cells in the pleural and peritoneal cavity, supporting our previous studies of several metastasis-associated molecules. The presence of cyclin-A-positive cell populations is associated with a more favorable disease outcome, possibly due to the targeting of proliferating cells by chemotherapeutic agents. However, the decline in the fraction of p27(kip1)-positive cells in posttreatment specimens may point to additional mechanisms involved in this selection. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11606079     DOI: 10.1006/gyno.2001.6388

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  11 in total

Review 1.  Adenocarcinoma cells in effusion cytology as a diagnostic pitfall with potential impact on clinical management: a case report with brief review of immunomarkers.

Authors:  Sinchita Roy Chowdhuri; Patricia Fetsch; Jennifer Squires; Elise Kohn; Armando C Filie
Journal:  Diagn Cytopathol       Date:  2012-11-16       Impact factor: 1.582

2.  EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma.

Authors:  Ben Davidson; Iris Goldberg; Aasmund Berner; Gunnar B Kristensen; Reuven Reich
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

3.  Unreported intrinsic disorder in proteins: Disorder emergency room.

Authors:  Vladimir N Uversky
Journal:  Intrinsically Disord Proteins       Date:  2015-04-22

4.  Expression of the 67 kDa laminin receptor and the alpha6 integrin subunit in serous ovarian carcinoma.

Authors:  Vered Givant-Horwitz; Ben Davidson; Gregg van de Putte; Hiep Phuc Dong; Iris Goldberg; Sivan Amir; Gunnar B Kristensen; Reuven Reich
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

5.  Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma.

Authors:  Ben Davidson; Vered Givant-Horwitz; Philip Lazarovici; Björn Risberg; Jahn M Nesland; Claes G Trope; Erik Schaefer; Reuven Reich
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

6.  Cyclin A2, a novel regulator of EMT.

Authors:  Nawal Bendris; Caroline T Cheung; Hon Sing Leong; John D Lewis; Ann F Chambers; Jean Marie Blanchard; Bénédicte Lemmers
Journal:  Cell Mol Life Sci       Date:  2014-05-31       Impact factor: 9.261

7.  A novel function for Cyclin A2: control of cell invasion via RhoA signaling.

Authors:  Nikola Arsic; Nawal Bendris; Marion Peter; Christina Begon-Pescia; Cosette Rebouissou; Gilles Gadéa; Nathalie Bouquier; Frédéric Bibeau; Bénédicte Lemmers; Jean Marie Blanchard
Journal:  J Cell Biol       Date:  2012-01-09       Impact factor: 10.539

8.  NM23-H1 expression of head and neck squamous cell carcinoma in association with the response to cisplatin treatment.

Authors:  Yi-Fen Wang; Chun-Ju Chang; Jen-Hwey Chiu; Chin-Ping Lin; Wing-Yin Li; Shyue-Yih Chang; Pen-Yuan Chu; Shyh-Kuan Tai; Yu-Jen Chen
Journal:  Oncotarget       Date:  2014-09-15

9.  Cyclin A2 regulates homologous recombination DNA repair and sensitivity to DNA damaging agents and poly(ADP-ribose) polymerase (PARP) inhibitors in human breast cancer cells.

Authors:  Wei Wei Gu; Jie Lin; Xing Yu Hong
Journal:  Oncotarget       Date:  2017-08-24

10.  Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies.

Authors:  Cécile Le Page; David G Huntsman; Diane M Provencher; Anne-Marie Mes-Masson
Journal:  Cancers (Basel)       Date:  2010-05-26       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.